Synthesis and study of L-dopa-glutathione codrugs as new anti-Parkinson agents with free radical scavenging properties

Journal of Medicinal Chemistry

Volumn 50, Issue 10, 2007, Pages 2506-2515

  Pinnen, Francesco ^a   Cacciatore, Ivana ^a   Cornacchia, Catia ^a   Sozio, Piera ^a   Iannitelli, Antonio ^a   Costa, Mara ^b   Pecci, Laura ^b   Nasuti, Cinzia ^c   Cantalamessa, Franco ^c   Di Stefano, Antonio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF CAMERINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLGLUTAMYL(CYSTEINYLGLYCYLLEVODOPA METHOXIDE)METHOXIDE; ACETYLLEVODOPA GLUTAMYL(CYSTEINYLGLYCINE METHOXIDE)METHOXIDE; AMIDE; ANTIPARKINSON AGENT; DEOXYRIBOSE; DOPAMINE; FERROUS ION; GLUTAMYL(CYSTEINYLGLYCYLLEVODOPA); GLUTATHIONE; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; LEVODOPA GLUTAMYL(CYSTEINYLGLYCINE); SCAVENGER; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; DRUG HYDROLYSIS; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME STABILITY; MALE; NONHUMAN; PARKINSON DISEASE; PARTITION COEFFICIENT; RAT; SUBSTANTIA NIGRA;

ADMINISTRATION, ORAL; ANIMALS; ANTIPARKINSON AGENTS; CORPUS STRIATUM; DOPAMINE; FREE RADICAL SCAVENGERS; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HUMANS; HYDROLYSIS; LEVODOPA; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; SUPEROXIDE DISMUTASE;

EID: 34248999408     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070037v     Document Type: Article

References (53)

1. Serra, P. A.; Esposito, G.; Enrico, P.; Mura, M. A.; Migheli, R.; Delogu, M. R.; Miele, M.; Desole, M. S.; Grella, G.; Miele, E. Manganese increases L-dopa auto-oxidation in the striatum of the freely moving rat: potential implications to L-dopa long-term therapy of Parkinson's disease. Br. J. Pharmacol. 2000, 130, 937-945.
2. Tofaris, G. K.; Spillantini, M. G. Alpha-synuclein dysfunction in Lewy body diseases. Mov. Disord. 2005, 20, S37-44.
3. Smith, T. S.; Parker, W. D., Jr.; Bennet, J. P., Jr. L-Dopa increases nigral production of hydroxyl radicals in vivo: potential L-Dopa toxicity? Neuroreport 1994, 5, 1009-1011.
4. Miller, J. W.; Selhub, J.; Joseph, J. A. Oxidative damage caused by free radicals produced during catecholamine autoxidation: protective effects of O-methylation and melatonin. Free Radical Biol. Med. 1996, 21, 241-249.
5. Enoch, W. S.; Sarna, T.; Zecca, L.; Riley, P. A.; Swartz, H. M. The roles of neuromelanin, binding of metal ions, and the oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis. J. Neural Transm. 1994, 7, 83-100.
6. Jellinger, K.; Linert, L.; Kienzl, E.; Herlinger, E.; Youdim, M. B. Chemical evidence for 6-hydroxydopamine to be a endogenous toxic factor in the pathogenesis of Parkinson's disease. J. Neural Transm. 1995, 46, S293-310.
7. Chinta, S. J.; Rajagopalan, S.; Butterfield, D. A.; Andersen, J. K. In vitro and in vivo neuroprotection by γ-glutamylcysteine ethyl ester against MPTP: Relevance to the role of glutathione in Parkinson's disease. Neurosci. Lett. 2006, 40, 137-141.
8. Bharath, S.; Hsu, M.; Kaur, D.; Rajagopalan, S.; Andersen, J. K. Glutathione, iron and Parkinson's disease. Biochem. Pharmacol. 2002, 40, 1037-1048.
9. Hsu, M.; Bharath, S.; Jyothi, K.; Rajagopalan, S.; Andersen, J. K. Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implication for Parkinson's disease. J. Neurochem. 2005, 92, 1091-1103.
10. Stadtman, E. R. Oxidation of free amino acids and amino acid residues in proteins by radiolysis and metal-catalyzed reactions. Annu. Rev. Biochem. 1993, 62, 797-821.
11. Rieder, P.; Dirr, A.; Goetz, M.; Sofic, E.; Youdim, M. B. H. Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann. Neurol. 1992, 32, S101-S104.
12. Williams-Gray, C. H.; Foltynie, T.; Lewis, S. J.; Barker, R. A. Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs 2006, 20, 477-505.
13. Bains, J. S.; Shaw, C. A. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res. Rev. 1997, 25, 335-358.
14. Albers, D. S.; Beal, M. F. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J. Neural Transm. 2000, 59, 133-154.
15. Jenner, P. Oxidative mechanism in nigral cell death in Parkinson's disease. Mov. Disord. 1998, 13, 24-34.
16. Spencer, J. P. E.; Jenner, P.; Daniel, S. E.; Lees, A. J.; Marsden, D. C.; Halliwell, B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: Possible mechanism of formation involving reactive oxygen species. J. Neurochem. 1998, 71, 2112-2122.
17. Andersen, J. K.; Mo, J. Q.; Hom, D. G.; Lee, F. Y.; Harnish, P.; Hamill, R. W.; McNeill, T. H. Effect of buthionine sulfoximine, a synthesis inhibitor of the antioxidant glutathione, on the murine nigrostriatal neurons. J. Neurochem. 1996, 67, 2164-2171.
18. Ravindranath, V.; Reed, D. J. Glutathione depletion and formation of glutathione-protein mixed disulfide following exposure of brain mitochondria to oxidative stress. Biochem. Biophys. Res. Commun. 1990, 29, 1075-1079.
19. Fornstedt, B.; Bergh, I.; Rosengren, E.; Carlsson, A. An improved HPLC-electrochemical detection method for measuring brain levels of 5-S-cysteinyldopamine, 5-S-cysteinyl-3,4-dihydroxyphenylalanine, and 5-S-cysteinyl-3,4-dihydroxyphenylacetic acid. J. Neurochem. 1990, 54, 578-586.
20. Hastings, T. G.; Lewis, D. A.; Zigmond, M. J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 1956-1961.
21. Sriram, K.; Shankar, S. K.; Boyd, M. R.; Ravindranath, V. Thiol oxidation and loss of mitochondrial complex I precede excitatory amino acid-mediated neurodegeneration. J. Neurosci. 1998, 18, 10287-10296.
22. Liochev, S. L. The role of iron-sulfur clusters in in vivo hydroxyl radical production. Free Radical Res. 1996, 25, 369-384.
23. Sechi, G.; Deledda, M. G.; Bua, G.; Satta, W. M.; Deiana, G. A.; Pes, G. M.; Rosati, G. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 1996, 20, 1159-1170.
24. Di Stefano, A.; Sozio, P.; Cocco, A.; Iannitelli, A.; Santucci, E.; Costa, M.; Pecci, L.; Nasuti, C.; Cantalamessa, F.; Pinnen, F. L-Dopa- and Dopamine-(R)-α-Lipoic acid conjugates as multifunctional codrugs with antioxidant properties. J. Med. Chem. 2006, 49, 1486-1493.
25. Rosini, M.; Andrisano, V.; Bartolini, M.; Bolognesi, M. L.; Hrelia, P.; Minarini, A.; Tarozzi, A.; Melchiorre, C. Rational approach to discover multipotent anti-Alzheimer drugs. J. Med. Chem. 2005, 48, 360-363.
26. Bharath, S.; Cochran, B. C.; Hsu, M.; Ames, B. N.; Andersen, J. K. Pre-treatment with R-Lipoic acid alleviates the effects of GSH depletion in PC12 cells: implications for Parkinson's disease therapy. Neurotoxicology 2002, 23, 479-486.
27. Jones, J. H. A short guide to abbreviations and their use in peptide science. J. Pept. Sci. 1999, 5, 465-471.
28. Bodor, N.; Sloan, K. B.; Higuchi, T.; Sasaha, K. Improved delivery through biological membranes. 4. Prodrugs of L-dopa. J. Med. Chem. 1977, 20, 1435-1445.
29. Banerjee, S. N.; Ressler, C. Derivatives of 3,4-dihydroxyphenylalanine for peptide synthesis. J. Org. Chem. 1976, 41, 3056-3058.
30. Chenault, H. K.; Dahmer, J.; Whitesides, G. M. Kinetic resolution of unnatural and rarely occurring amino acids: enantioselective hydrolysis of N-acyl amino acids catalyzed by acylase I. J. Am. Chem. Soc. 1989, 111, 6354-6364.
31. Yalkowsky, S. H.; Morzowich, W. In Drug Design; Ariens, J., Ed.; Academic: New York, 1980; Vol. IX, p 121.
32. Grant, D. J. W.; Higuchi, T. Solubility and partitioning into water. In Solubility behaviour of organic compounds; Wiley: New York, 1990; pp 164-175.
33. Yalkowsky, S. H.; Banerjee, S. Aqueous solubility: Methods of estimation for organic compounds; Marcel Dekker: New York, 1992.
34. Streng, W. H. Partitioning: Experimental procedures and example. In Characterization of compounds in solution - Theory and practice; Kluwer Academic/Plenum Publishers: New York, 2001; pp 161-180.
35. Mack, F.; Boenisch, H. Dissociation constants and lipophilicity of catecholamines and related compounds. Arch. Pharmacol. 1979, 310, 1-9.
36. Farghaly, A. O. Cyclic amide derivatives as potential prodrugs. Synthesis and evaluation of N-hydroxymethylphthalimide esters of some non-steroidal anti-inflammatory carboxylic acid drugs. Eur. J. Med. Chem. 1998, 33, 123-131.
37. Welch, R. M.; Brown, A.; Ravitch, J.; Dahl, R. The in vitro degradation of cisatracurium, the R,cis-R′-isomer of atracurium, in human and rat plasma. Clin. Pharmacol. Ther. 1995, 58, 132-142.
38. Nasuti, C.; Gabbianelli, R.; Falcioni, M. L.; Di Stefano, A.; Sozio, P.; Cantalamessa, F. Dopaminergic system modulation, behavioral changes, and oxidative stress after neonatal administration of pyrethroids. Toxicology 2007, 229, 194-205.
39. Gundert-Remy, U.; Hildebrand, R.; Stiehl, A.; Weber, E.; Zurcher, G.; Da Prada, M. Intestinal absorption of levodopa in man. Eur. J. Clin. Pharmacol. 1983, 25, 69-72.
40. Da Prada, M.; Keller, H. H.; Pieri, L.; Kettler, L.; Haefely, W. E. The pharmacology of Parkinson's disease: basic aspects and recent advances. Experientia 1984, 40, 1165-1172.
41. Michiels, C.; Raes, M.; Topussaint, O.; Remacle, J. Importance of Se-glutathione peroxidase, catalase, and Cu/Zn-SOD for cell survival against oxidative stress. Free Radical Biol. Med. 1994, 17, 235-248.
42. Nappi, A. J.; Vass, E. Comparative studies of enhanced iron-mediated production of hydroxyl radical by glutathione, cysteine, ascorbic acid, and selected catechols. Biochim. Biophys. Acta 1997, 1336, 295-301.
43. Kim-Han, J. S.; Sun, A. Y. Protection of PC12 cells by glutathione peroxidase in L-dopa induced cytotoxicity. Free Radical Biol. Med. 1998, 25, 512-518.
44. Spencer, J. P. E.; Jenner, A.; Butler, J.; Aruoma, O. I.; Dexter, D. T.; Jenner, P.; Halliwell, B. Evaluation of the pro-oxidant and antioxidant actions of L-dopa and dopamine in vitro: implications for Parkinson's disease. Free Rad. Res. 1996, 24, 95-105.
45. Nasuti, C.; Cantalamessa, F.; Falcioni, G.; Gabbianelli, R. Different effects of type I and type II pyrethroids on erythrocyte plasma membrane properties and enzymatic activity in rats. Toxicology 2003, 191, 233-244.
46. Saggu, H.; Cooksey, J.; Dexter, D.; Wells, F. R.; Lees, A.; Jenner, P.; Marsden, C. D. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. 1998, 53, 692-697.
47. Berridge, K. C. Substantia nigra 6-OHDA lesions mimic striatopallidal disruption of syntactic grooming chains: a neural systems analysis of sequence control. Psychobiology 1989, 17, 377-385
48. Berridge, K. C.; Aldridge, J. W. Super-stereotypy. Enhancement of a complex movement sequence by systemic dopamine D1 agonists. Synapse 2000, 37, 194-204.
49. Eguibar, J. R.; Moyaho, A. Inhibition of grooming by pilocarpine differs in high- and low-yawning sublines of Sprague-Dawley rats. Pharmacol. Biochem. Behav. 1997, 58, 317-322.
50. Halliwel, B.; Gutteridge, J. M. C.; Aruoma, O. I. The deoxyribose method: a simple "Test-Tube" assay for determination of rate constants for reactions of hydroxyl radicals. Anal. Biochem. 1987, 165, 215-219.
51. Paglia, D. E.; Valentine, W. N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 1967, 276, 368-374.
52. Nebot, C.; Moutet, M.; Huet, P.; Xu, J. Z.; Yadan, J. C. Spectrophotometric assay of superoxide dismutase activity based on the activated autoxidation of a tetracyclic catechol. Anal. Biochem. 1993, 214, 442-441.
53. Contò, M. B.; de Carvalho, J. G.; Benedito, M. A. Behavioral difference between subgroups of rats with high and low threshold to clonic convulsions induced by DMCM, a benzodiazepine inverse agonist. Pharmacol., Biochem. Behav. 2005, 82, 417-426.